<ul>
<li>Corvus Pharmaceuticals President and CEO Richard A. Miller bought 6,932 shares of common stock through a family trust.     *      The purchases were reported at prices of USD 12.05 and USD 12.01 per share.     *      The trust’s holdings rose to 1,195,035 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000160), on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

CRVS

LABU

SBIO

IBBQ

<p>Corvus Pharmaceuticals CEO Richard A. Miller purchased 6,932 shares of common stock through a family trust for a total of USD 83,112, at prices of USD 12.05 and USD 12.01 per share. The trust's total holdings increased to 1,195,035 shares after the transaction.</p>

PUBT

Corvus Pharma

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Corvus CEO Richard Miller reports trust buy of USD 83,112 common shares